Anavex Life Sciences Corp


Prices are adjusted according to historical splits.

Anavex Life Sciences Corp Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$744.43 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Anavex Life Sciences Corp had its IPO on 2006-08-02 under the ticker symbol AVXL.

The company operates in the Healthcare sector and Biotechnology industry. Anavex Life Sciences Corp has a staff strength of 38 employees.

Stock update

Shares of Anavex Life Sciences Corp opened at $9.4 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $9.21 - $9.55, and closed at $9.51.

This is a -0.31% slip from the previous day's closing price.

A total volume of 1,908,500 shares were traded at the close of the day’s session.

In the last one week, shares of Anavex Life Sciences Corp have slipped by -1.76%.

Anavex Life Sciences Corp's Key Ratios

Anavex Life Sciences Corp has a market cap of $744.43 million, indicating a price to book ratio of 4.8312 and a price to sales ratio of 0.

In the last 12-months Anavex Life Sciences Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Anavex Life Sciences Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Anavex Life Sciences Corp’s operating margin was 0% while its return on assets stood at -21.05% with a return of equity of -35.57%.

In Q4, Anavex Life Sciences Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Anavex Life Sciences Corp’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Anavex Life Sciences Corp’s profitability.

Anavex Life Sciences Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -10.5764. Its price to sales ratio in the trailing 12-months stood at 0.

Anavex Life Sciences Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$148.37 million
Total Liabilities
$6.21 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Anavex Life Sciences Corp ended 2023 with $148.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $148.37 million while shareholder equity stood at $135.12 million.

Anavex Life Sciences Corp ended 2023 with $0 in deferred long-term liabilities, $6.21 million in other current liabilities, 78033.00 in common stock, $-258535501.00 in retained earnings and $0 in goodwill. Its cash balance stood at $143.62 million and cash and short-term investments were $143.62 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Anavex Life Sciences Corp’s total current assets stands at $143.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.09 million compared to accounts payable of $5.29 million and inventory worth $0.

In 2023, Anavex Life Sciences Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Anavex Life Sciences Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Anavex Life Sciences Corp stock is currently trading at $9.51 per share. It touched a 52-week high of $15.24 and a 52-week low of $15.24. Analysts tracking the stock have a 12-month average target price of $43.

Its 50-day moving average was $10.25 and 200-day moving average was $10.34 The short ratio stood at 14.94 indicating a short percent outstanding of 0%.

Around 304.3% of the company’s stock are held by insiders while 3520.3% are held by institutions.

Frequently Asked Questions About Anavex Life Sciences Corp

The stock symbol (also called stock or share ticker) of Anavex Life Sciences Corp is AVXL

The IPO of Anavex Life Sciences Corp took place on 2006-08-02

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.


630 5th Avenue, New York, NY, United States, 10111